Daratumumab, dexamethasone, ixazomib, pomalidomide for Relapsed Or Refractory Multiple Myeloma

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Relapsed Or Refractory Multiple Myeloma+2 More
Daratumumab, dexamethasone, ixazomib, pomalidomide - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is a precision medicine study to treat patients with drugs targeted to affect specific genes that are mutated as part of the disease.

Eligible Conditions
  • Relapsed Or Refractory Multiple Myeloma

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Relapsed Or Refractory Multiple Myeloma

Study Objectives

2 Primary · 0 Secondary · Reporting Duration: Patients will be evaluated monthly for response from the start of the study until the date of documented disease progression, assessed up to 2 years

Year 2
Overall Response Rate - Actionable Genetic Alteration
Overall Response Rate - Non-Actionable Genetic Alteration

Trial Safety

Safety Progress

1 of 3

Other trials for Relapsed Or Refractory Multiple Myeloma

Trial Design

8 Treatment Groups

Sub-Protocol Y2
1 of 8
Sub-Protocol B1
1 of 8
Sub-Protocol C1
1 of 8
Sub-Protocol A1
1 of 8
Sub-Protocol Y1
1 of 8
Sub-Protocol E1
1 of 8
Sub-Protocol Y3
1 of 8
Sub-Protocol D1
1 of 8
Experimental Treatment

228 Total Participants · 8 Treatment Groups

Primary Treatment: Daratumumab, dexamethasone, ixazomib, pomalidomide · No Placebo Group · Phase 1 & 2

Sub-Protocol Y2
Drug
Experimental Group · 1 Intervention: Belantamab mafodotin, dexamethasone, ixazomib, pomalidomide · Intervention Types: Drug
Sub-Protocol B1
Drug
Experimental Group · 1 Intervention: Enasidenib, dexamethasone, ixazomib, pomalidomide · Intervention Types: Drug
Sub-Protocol C1
Drug
Experimental Group · 1 Intervention: Cobimetinib, dexamethasone, ixazomib, pomalidomide · Intervention Types: Drug
Sub-Protocol A1
Drug
Experimental Group · 1 Intervention: Abemaciclib, dexamethasone, ixazomib, pomalidomide · Intervention Types: Drug
Sub-Protocol Y1
Drug
Experimental Group · 1 Intervention: Daratumumab, dexamethasone, ixazomib, pomalidomide · Intervention Types: Drug
Sub-Protocol E1
Drug
Experimental Group · 1 Intervention: Venetoclax, dexamethasone, ixazomib, pomalidomide · Intervention Types: Drug
Sub-Protocol Y3
Drug
Experimental Group · 1 Intervention: Selinexor, dexamethasone, ixazomib, pomalidomide · Intervention Types: Drug
Sub-Protocol D1
Drug
Experimental Group · 1 Intervention: Erdafitinib, dexamethasone, ixazomib, pomalidomide · Intervention Types: Drug

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: patients will be evaluated monthly for response from the start of the study until the date of documented disease progression, assessed up to 2 years

Who is running the clinical trial?

TakedaIndustry Sponsor
1,107 Previous Clinical Trials
4,040,832 Total Patients Enrolled
10 Trials studying Relapsed Or Refractory Multiple Myeloma
1,499 Patients Enrolled for Relapsed Or Refractory Multiple Myeloma
Multiple Myeloma Research ConsortiumLead Sponsor
18 Previous Clinical Trials
972 Total Patients Enrolled
1 Trials studying Relapsed Or Refractory Multiple Myeloma
104 Patients Enrolled for Relapsed Or Refractory Multiple Myeloma
Karyopharm Therapeutics IncIndustry Sponsor
84 Previous Clinical Trials
7,915 Total Patients Enrolled
3 Trials studying Relapsed Or Refractory Multiple Myeloma
328 Patients Enrolled for Relapsed Or Refractory Multiple Myeloma
Genentech, Inc.Industry Sponsor
1,486 Previous Clinical Trials
563,691 Total Patients Enrolled
3 Trials studying Relapsed Or Refractory Multiple Myeloma
474 Patients Enrolled for Relapsed Or Refractory Multiple Myeloma
GlaxoSmithKlineIndustry Sponsor
4,635 Previous Clinical Trials
7,942,254 Total Patients Enrolled
1 Trials studying Relapsed Or Refractory Multiple Myeloma
96 Patients Enrolled for Relapsed Or Refractory Multiple Myeloma
Eli Lilly and CompanyIndustry Sponsor
2,451 Previous Clinical Trials
3,120,456 Total Patients Enrolled
AbbVieIndustry Sponsor
822 Previous Clinical Trials
469,377 Total Patients Enrolled
6 Trials studying Relapsed Or Refractory Multiple Myeloma
558 Patients Enrolled for Relapsed Or Refractory Multiple Myeloma
Celgene CorporationIndustry Sponsor
441 Previous Clinical Trials
56,541 Total Patients Enrolled
Janssen, LPIndustry Sponsor
144 Previous Clinical Trials
200,099 Total Patients Enrolled
1 Trials studying Relapsed Or Refractory Multiple Myeloma
46 Patients Enrolled for Relapsed Or Refractory Multiple Myeloma
Hearn J Cho, M.D., Ph.D.Principal InvestigatorMultiple Myeloma Research Consortium
Daniel Auclair, Ph.D.Principal InvestigatorMultiple Myeloma Research Consortium
1 Previous Clinical Trials
104 Total Patients Enrolled
1 Trials studying Relapsed Or Refractory Multiple Myeloma
104 Patients Enrolled for Relapsed Or Refractory Multiple Myeloma

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You have not had a prior malignancy for at least 3 years with the exception of basal cell, squamous cell carcinoma of the skin, carcinoma \"in situ\" of the cervix or breast, or prostate cancer not requiring therapy.
You have relapsed within 3 years of initiation of induction chemo therapy for post ASCT followed by maintenance, or 18 months if unmaintained after ASCT.
You had early relapse after initial treatment.
Patients must have progressed after their most recent treatment and require therapy for myeloma.
You are female and of reproductive potential.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 12th, 2021

Last Reviewed: October 22nd, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.